In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated patients whose disease met established diagnostic criteria were entered into a prospective, randomized controlled trial between 1967 and 1974. Three treatment regimens were used: phlebotomy alone, chlorambucil supplemented by phlebotomy, or radioactive phosphorus supplemented by phlebotomy. Despite minor differences in age and sex, the three groups were comparable in initial hematocrit, white-cell and platelet counts, and disease-related symptoms. The median duration of follow-up is now more than 6 1/2 years. As of February 15, 1980, there were no statistically significant differences in survival among the groups. However, the risk of acute leukemia in patients given chlorambucil was 2.3 times that in patients given radioactive phosphorus and 13 times that in patients treated with phlebotomy alone. The increased incidence of leukemia during chlorambucil treatment is statistically significant (P less than or equal to 0.002); accordingly, the Polycythemia Vera Study Group has discontinued the use of chlorambucil in the treatment of polycythemia vera.
This article has been cited by other articles:
Levine, R. L., Gilliland, D. G.
(2008). Myeloproliferative disorders. Blood
112: 2190-2198
[Abstract][Full Text]
Spivak, J. L., Silver, R. T.
(2008). The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood
112: 231-239
[Full Text]
Harrison, B. R., Peters, B. G., Bing, M. R.
(2006). Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.. Am J Health Syst Pharm
63: 1736-1744
[Abstract][Full Text]
Schafer, A. I.
(2006). Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood
107: 4214-4222
[Abstract][Full Text]
Burkitt, M. J., Raafat, A.
(2006). Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood
107: 2219-2222
[Abstract][Full Text]
Campbell, P. J., Green, A. R.
(2006). The Long-term Outlook for Essential Thrombocythemia. Mayo Clin. Proc.
81: 157-158
[Full Text]
Gordon, L. I.
(2005). Flu redux and RIT: friendly fire in the treatment of low-grade lymphoma. Blood
105: 4543-4544
[Full Text]
Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., Capizzi, R. L.
(2005). Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood
105: 4576-4582
[Abstract][Full Text]
Marchioli, R., Finazzi, G., Landolfi, R., Kutti, J., Gisslinger, H., Patrono, C., Marilus, R., Villegas, A., Tognoni, G., Barbui, T.
(2005). Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. JCO
23: 2224-2232
[Abstract][Full Text]
Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E. M., Randi, M. L., Villegas, A., Tognoni, G., Barbui, T., for the ECLAP Investigators,
(2005). Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood
105: 2664-2670
[Abstract][Full Text]
Spivak, J. L., Barosi, G., Tognoni, G., Barbui, T., Finazzi, G., Marchioli, R., Marchetti, M.
(2003). Chronic Myeloproliferative Disorders. ASH Education Book
2003: 200-224
[Abstract][Full Text]
Spivak, J. L.
(2002). Polycythemia vera: myths, mechanisms, and management. Blood
100: 4272-4290
[Full Text]
Weldon, C. B., Jaffe, B. M., Kahn, M. J.
(2002). Therapy-Induced Leukemias and Myelodysplastic Syndromes After Breast Cancer Treatment: An Underemphasized Clinical Problem. Ann. Surg. Oncol.
9: 738-744
[Full Text]
Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., Appelbaum, F. R., Hines, J. D., Shepherd, L., Larson, R. A., Schiffer, C. A.
(2002). Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. JCO
20: 3878-3884
[Abstract][Full Text]
Streiff, M. B., Smith, B., Spivak, J. L.
(2002). The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood
99: 1144-1149
[Abstract][Full Text]
Grunwald, H. W., Rosner, F., Dighiero, G., Travade, P., Binet, J.-L., The French Cooperative Group on Chronic Lymphocyti,
(1998). Secondary Acute Leukemia in Chronic Lymphocytic Leukemia. NEJM
339: 924-924
[Full Text]
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., Binet, J.-L., Travade, P., Turpin, F.-L., Tertian, G., Bichoffe, A., The French Cooperative Group on Chronic Lymphocyti,
(1998). Chlorambucil in Indolent Chronic Lymphocytic Leukemia. NEJM
338: 1506-1514
[Abstract][Full Text]
Gonda, T. J., D'Andrea, R. J.
(1997). Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease. Blood
89: 355-369
[Full Text]
Schieppati, A., Mosconi, L., Perna, A., Mecca, G., Bertani, T., Garattini, S., Remuzzi, G.
(1993). Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. NEJM
329: 85-89
[Abstract][Full Text]
Burgaz, S., Ozdamar, Y.N., Karakaya, A.E.
(1988). A Signal Assay for the Detection of Genotoxic Compounds: Application on the Urines of Cancer Patients on Chemotherapy and of Nurses Handling Cytotoxic Drugs. Hum Exp Toxicol
7: 557-560
[Abstract]
